The increased G-CSF prescription due to the pandemic was more frequent in the MENA representatives (OR 0.75, 95% CI 1.53–6.02, p = 0.001) and tended to be positively associated with the reported G-CSF usage in high-risk afebrile neutropenia (OR 4.75, 95% CI 0.94–23.95, p = 0.059), but not to any other choices in the field of neutropenia treatment. The gene discussed is CSF3; the disease is neutropenia.